Societal CDMO to Report Financial Results for First Quarter 2023 on May 10, 2023
03 mai 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., May 03, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO)...
PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin
25 avr. 2023 08h00 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (MDMA.CSE) is excited to have received a signed purchase order for GMP LaNeo MDMA and Psilocybin by Incannex...
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
25 avr. 2023 02h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
18 avr. 2023 09h00 HE
|
EvolveImmune
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1 Checkpoint Pathway Engineered CAR-T Cells Lacking Exhaustion-Associated Genes Mediate Improved...
Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU
14 avr. 2023 07h30 HE
|
Incannex Healthcare
MELBOURNE, Australia, April 14, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal...
PharmAla Biotech and Filament Health Announce Release of GMP MDMA Capsules
11 avr. 2023 08h00 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, April 11, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA), a Canadian biotechnology company dedicated to the research and development of...
Societal CDMO Reports Inducement Grants for New Staff
06 avr. 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., April 06, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
Harmony Biosciences Holdings Shareholder News: Johnson Fistel Urges Investors with Losses to Reach Out Regarding Class Action Investigation - HRMY
28 mars 2023 19h30 HE
|
Johnson Fistel, LLP
SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY), any of its executive...
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
15 mars 2023 16h11 HE
|
Catalyst Pharmaceuticals, Inc.
Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY Increase Newly Acquired FYCOMPA® Product...
Dyspepsia Treatment Market to advancement at a CAGR of 4.1% during 2022–2031, as demand for non-invasive treatment is growing | TMR Study
10 mars 2023 14h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, March 11, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. – In 2021, the Global Dyspareunia Treatment Market size was worth US$ 689.0 Mn. Dyspareunia...